Mereo BioPharma Group plc

Equities

MREO

US5894921072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 24/05/2024 am IST			5-day change	1st Jan Change
2.93 ^USD	-2.01%		-10.40%	+26.84%

22/05	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
17/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT

Mereo Biopharma Group plc Appoints Michael Wyzga as Interim Chief Financial Officer

August 03, 2020 at 06:47 pm IST

Mereo BioPharma Group plc announced that effective August 1, 2020, current Mereo Board of Directors member Michael Wyzga became Interim Chief Financial Officer of Mereo following the planned departure of Mr. Richard Jones, the Company’s Chief Financial Officer, who previously informed Mereo’s Board of Directors that he would be leaving the Company to pursue other opportunities.

Latest news about Mereo BioPharma Group plc

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	16/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	01/05	MT
European Equities Traded in the US as American Depositary Receipts Decline	30/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	26/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	24/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	09/04	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	08/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	03/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	01/04	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	28/03	MT
Needham Adjusts Price Target on Mereo BioPharma to $6 From $5, Keeps Buy Rating	28/03	MT
Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25/03	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	22/03	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21/03	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	15/03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	29/02	MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%	23/02	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading	05/02	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Higher	02/02	MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading	01/02	MT

Chart Mereo BioPharma Group plc

Duration

Period

More charts

Company Profile

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Sector

Biotechnology & Medical Research

Calendar

17/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mereo BioPharma Group plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.305 GBP

Average target price

4.959 GBP

Spread / Average Target

+115.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEREO BIOPHARMA GROUP PLC	+26.84%	42Cr
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.65%	11TCr
BIONTECH SE	-6.20%	2.47TCr
ARGENX SE	-2.33%	2.2TCr
GENMAB A/S	-6.03%	1.93TCr
BEIGENE, LTD.	-13.41%	1.76TCr
WUXI APPTEC CO., LTD.	-40.50%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+6.64%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+31.84%	1.21TCr

Bio Therapeutic Drugs